Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment

Journal of Human Hypertension

Volumn 17, Issue 2, 2003, Pages 119-124

  Zervoudaki, A ^a   Economou, E ^a   Stefanadis, C ^a   Pitsavos, C ^a   Tsioufis, K ^a   Aggeli, C ^a   Vasiliadou, K ^a   Toutouza, M ^a   Toutouzas, P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Extracellular matrix; Metalloproteinases; Vascular remodelling

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; GELATINASE A; GELATINASE B; GLUCOSE; POTASSIUM;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN METABOLISM; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; ENZYME BLOOD LEVEL; ENZYME SPECIFICITY; ESSENTIAL HYPERTENSION; EXTRACELLULAR MATRIX; FEMALE; HEART; HEART HEMODYNAMICS; HEART VENTRICLE REMODELING; HUMAN; HYPOTHESIS; LONG TERM CARE; MALE; NORMAL VALUE; POTASSIUM BLOOD LEVEL; TISSUE REPAIR; TREATMENT OUTCOME; TREATMENT PLANNING; VASCULAR RESISTANCE;

ADULT; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TIME FACTORS; VASCULAR RESISTANCE;

EID: 0037291886     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001518     Document Type: Article

References (25)

1. Pardo-Mindan FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 1993; 14 (Suppl J): 12-14.
2. Chevalier B et al. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation 1995; 2: 1947-1953.
3. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312-318.
4. Laurent S. Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension 1995; 26: 355-362.
5. Madhavan S et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401.
6. Brush Jr JE et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988; 318: 1302-1307.
7. Heagerty AM et al. Small artery structure in hypertension: Dual process of remodeling and growth. Hypertension 1993; 21: 391-397.
8. Gariepy J et al. Evidence for in vivo carotid and femoral wall thickening in human hypertension. Hypertension 1993; 22: 111.
9. Tyagi SC. Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 1998; 168: 1-12.
10. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension. Roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38 (Part 2): 581-587.
11. Laviades C et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540.
12. Brilla CG et al. Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease for hypertrophic cardiomyopathy. Circulation 1994; 90 (Suppl I): I-264 (abstract).
13. Li-Saw-Hee FL, Edmunds E, Blann AD et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75: 43-47.
14. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55: 613-618.
15. Ganau A et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558.
16. Quinones MA, Pickering E, Alexander JK. Percentage of shortening of the echocardiographic left ventricular dimension: Its use in determining ejection fraction and stroke volume. Chest 1978; 74: 59-65.
17. Dupin J et al. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J 1990; 20: 116-123.
18. Vensel LA et al. Cardiac structure and function in renovascular hypertension produced by unilateral and bilateral renal artery stenosis. Am J Cardiol 1986; 58: 575-582.
19. Intengan HD, Schiffrin EL. Collagen degradation is diminished in mesenteric arteries of spontaneously hypertensive rats after hypertension is established. Hypertension 1999; 37: 329 (abstract).
20. Tamarina NA et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122: 264-272.
21. Yo Li Y et al. Differential expression of tissue inhibitors of metalloproteinases in the failing heart. Circulation 1998; 98: 1728-1734.
22. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478-5482.
23. Kohn E et al. A Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 1994; 269: 21505-21511.
24. Lohi J, Keski-Oja J. Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J Biol Chem 1995; 270: 17602-17609.
25. Eickelberg O, Roth M, Lutz-Henning LH. Effects of amlodipine in gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: Implications for vascular protection. Int J Cardiol 1997; 62 (Suppl 2): S31-S37.